Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect Syndax Pharmaceuticals to post earnings of ($1.24) per share and revenue of $15.88 million for the quarter.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Syndax Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ SNDX traded down $0.09 during mid-day trading on Friday, reaching $13.73. 2,274,577 shares of the company were exchanged, compared to its average volume of 1,613,844. The stock has a market capitalization of $1.18 billion, a P/E ratio of -3.78 and a beta of 0.82. The company's 50-day simple moving average is $12.89 and its 200-day simple moving average is $14.67. Syndax Pharmaceuticals has a twelve month low of $9.66 and a twelve month high of $25.07.

Insider Activity at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. The trade was a 5.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares of the company's stock, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock valued at $336,087 over the last three months. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SNDX. Scotiabank reduced their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Citigroup dropped their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).